Quantcast
Last updated on April 16, 2014 at 10:23 EDT

Latest MedImmune Stories

Researchers Make Universal One-Time Influenza Vaccine
2012-12-18 15:44:38

Lee Rannals for redOrbit.com — Your Universe Online Researchers at Georgia State University's Center for Inflammation, Immunity and Infection (CIII) discovered a new process to make a one-time, universal influenza vaccine. The team found a way to make the one-time vaccine by using recombinant genetic engineering technology that does not use seasonal virus. The new vaccine uses a virus' small fragment that does not vary among the different strains of flu viruses. By using the...

2012-12-17 08:25:53

GAITHERSBURG, Md., Dec. 17, 2012 /PRNewswire/ -- MedImmune, the global biologics arm of AstraZeneca, announced that it has signed an in-licensing agreement with Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) for Progenics' Clostridium difficile late-stage preclinical program. The agreement was led by MedImmune's Infectious Diseases & Vaccines Innovative Medicines (iMed) Unit. Clostridium difficile infections are the leading cause of hospital-acquired bacterial infections in the U.S. and...

2012-12-03 21:10:09

College football and basketball games may provide more than a way for students to show school spirit — they could help prevent the flu. According to a new study by researchers at Wake Forest Baptist Medical Center, colleges and universities should implement new or improved influenza vaccine strategies, such as giving flu shots at sporting events or during campus-wide, day-long campaigns, to increase the number of their students who get the annual flu vaccine. In the early online...

2012-11-20 20:23:34

CAMBRIDGE, Mass., Nov. 20, 2012 /PRNewswire/ -- Novartis announced today that the US Food and Drug Administration (FDA) approved the use of Flucelvax(®) (Influenza Virus Vaccine), the first cell-culture-derived vaccine, for individuals 18 years of age and older(3). Flucelvax utilizes full-scale cell-culture manufacturing technology, an alternative production method to traditional egg-based production(1). Cell-culture technology utilizes a well-characterized mammalian cell line rather...

2012-11-09 20:22:00

- Provides Update on Seasonal and Pandemic Influenza Programs - QUEBEC CITY, Nov. 9, 2012 /PRNewswire/ - Medicago Inc. (TSX: MDG)(OTCQX: MDCGF), a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles ("VLPs"), today announced its operational and financial results for the third quarter ended September 30, 2012. The Company's financial statements and management report are...

2012-10-22 07:30:11

LADERA RANCH, Calif., Oct. 22, 2012 /PRNewswire/ -- Advanced Biologics announced today that they will be releasing data at the North American Spine Society (NASS) annual meeting this week in Dallas, TX showcasing a clinical study demonstrating superior lumbar fusion rates for OsteoAMP® when compared to rhBMP-2 (Infuse®, Medtronic). In a blinded, multi-center clinical and radiological study, fusion analysis of 221 patients showed superiority for OsteoAMP® in producing fusions when...

2012-10-19 15:22:42

GAITHERSBURG, Md., Oct. 19, 2012 /PRNewswire/ -- MedImmune, the global biologics arm of AstraZeneca, announced today it will present three influenza abstracts at IDWeek 2012: the first combined meeting of the Infectious Diseases Society of America, the Society for Healthcare Epidemiology of America, the HIV Medicine Association, and the Pediatric Infectious Diseases Society, in San Diego, California, October 17-21, 2012. These abstracts expand upon the existing body of knowledge and data...

2012-10-09 11:28:21

GAITHERSBURG, Md., Oct. 9, 2012 /PRNewswire/ -- MedImmune, the global biologics arm of AstraZeneca, announced today it will present four abstracts at the Influenza Vaccines for the World (IVW) International Conference at the Palacio de Congresos de Valencia, Valencia, Spain, October 9-12, 2012. These abstracts advance the body of existing data and knowledge surrounding influenza vaccination, highlighting MedImmune's continued leadership in helping to improve patient health. MedImmune...

2012-10-09 07:29:00

NEW YORK and GAITHERSBURG, Md., Oct. 9, 2012 /PRNewswire/ -- The Cancer Research Institute (CRI), the Ludwig Institute for Cancer Research and MedImmune, the global biologics arm of AstraZeneca, today announced that they have signed a collaboration agreement to advance the research of immunotherapy in cancer. Specifically, the research will focus on clinical trials to test novel combinations of immunotherapies, including three investigational monoclonal antibodies from MedImmune's pipeline....

2012-10-03 06:25:54

GAITHERSBURG, Md., Oct. 3, 2012 /PRNewswire/ -- MedImmune, the biologics arm of AstraZeneca, today announced that the Journal of Medical Economics has published a study that shows Synagis® (palivizumab) is within the acceptable range of cost effectiveness. Specifically, the study relates to Synagis' reduction in hospitalizations due to serious respiratory syncytial virus (RSV) disease among eligible preterm infant populations covered by Medicaid and private insurers in the United States...